Physician profile
Patrick A Laperouse
NPI 1801901335
$3,288.37
in general payments reported to CMS, 2019-2025
30 companies · $829 in 2025
The $829 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $374 · 2020: $256 · 2021: $467 · 2022: $400 · 2023: $510 · 2024: $453 · 2025: $829.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.06 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $759.93 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $508.78 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $319.22 | 2019-2025 | |
| Janssen Biotech, INC. | $295.76 | 2020-2025 | Stelara, Tremfya, Simponi |
| Genzyme Corporation | $236.07 | 2023-2025 | |
| Pfizer INC. | $149.03 | 2019-2025 | |
| Celgene Corporation | $105.11 | 2021-2023 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.84 | 2019-2025 | Relistor |
| Ardelyx, INC. | $91.50 | 2023-2024 | Ibsrela |
| Romark Laboratories, Lc | $89.36 | 2019-2020 | |
| Qol Medical, LLC | $85.94 | 2020-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $75.09 | 2019-2023 | Injectafer |
| Boston Scientific Corporation | $60.79 | 2025 | Exalt Model D |
| Ironwood Pharmaceuticals, INC | $60.65 | 2020-2021 | |
| Madrigal Pharmaceuticals | $47.42 | 2024-2025 | Rezdiffra, Resmetirom |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $47.20 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $33.16 | 2024-2025 | Vegzelma, Zymfentra |
| Lilly USA, LLC | $31.41 | 2024-2025 | Omvoh |
| Shield Therapeutics INC | $20.21 | 2023 | Accrufer |
| Fresenius Kabi USA, LLC | $19.76 | 2023 | Idacio |
| Ipsen Biopharmaceuticals, INC | $18.19 | 2025 | Iqirvo |
| Novo Nordisk INC | $17.84 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $17.21 | 2021 | |
| Aimmune Therapeutics, INC. | $16.91 | 2025 | Zenpep |
| Concordia Pharmaceuticals INC. | $16.29 | 2019 | |
| Intercept Pharmaceuticals, INC. | $16.09 | 2022 | |
| Mallinckrodt Hospital Products INC. | $14.42 | 2023 | Terlivaz |
| Merck Sharp & Dohme LLC | $13.78 | 2024 | Dificid |
| Braintree Laboratories, INC. | $13.34 | 2021 | |
| Ucb, INC. | $13.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Laperouse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.